Pyrrolotriazine kinase inhibitors
US7605160B2 · kind B2 · utility
20Cited by
3References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 8, 2007 |
| Grant date | Oct 20, 2009 |
| Priority date | — |
| Expiry date | Aug 8, 2027 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides compounds of formula Iand pharmaceutically acceptable salts thereof.The formula I compounds inhibit tyrosine kinase activity of Trk receptors such as TrkA, TrkB and TrkC thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.